Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer

Overview of attention for article published in Breast Cancer Research, December 2010

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

patent: 2 patents

Citations

dimensions_citation: 75 Dimensions

Readers on

mendeley: 49 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

MCL-1 as a therapeutic target in SCFFBW7 deficient neoplasm

Grant US-10006089-B2

United States of America

MCL-1 AS A THERAPEUTIC TARGET IN SCFFBW7 DEFICIENT NEOPLASM

Application WO-2012119091-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.